Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans

Yukiko Kimura, Laura E Schanberg, George A Tomlinson, Mary Ellen Riordan, Anne C Dennos, Vincent Del Gaizo, Katherine L Murphy, Pamela F Weiss, Marc D Natter, Brian M Feldman, Sarah Ringold, CARRA STOP-JIA Investigators

Abstract

Objective: The optimal time to start biologics in polyarticular juvenile idiopathic arthritis (JIA) remains uncertain. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed 3 consensus treatment plans (CTPs) for untreated polyarticular JIA to compare strategies for starting biologics.

Methods: Start Time Optimization of Biologics in Polyarticular JIA (STOP-JIA) was a prospective, observational, CARRA Registry study comparing the effectiveness of 3 CTPs: 1) the step-up plan (initial nonbiologic disease-modifying antirheumatic drug [DMARD] monotherapy, adding a biologic if needed, 2) the early combination plan (DMARD and biologic started together), and 3) the biologic first plan (biologic monotherapy). The primary outcome measure was clinically inactive disease according to the provisional American College of Rheumatology (ACR) criteria, without glucocorticoids, at 12 months. Secondary outcome measures included Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference and mobility scores, inactive disease as defined by the clinical Juvenile Arthritis Disease Activity Score in 10 joints (JADAS-10), and the ACR Pediatric 70 criteria (Pedi 70).

Results: Of 400 patients enrolled, 257 (64%) began the step-up plan, 100 (25%) the early combination plan, and 43 (11%) the biologic first plan. After propensity score weighting and multiple imputation, clinically inactive disease according to the ACR criteria was achieved in 37% of those on the early combination plan, 32% on the step-up plan, and 24% on the biologic first plan (P = 0.17). Inactive disease according to the clinical JADAS-10 (score ≤2.5) was also achieved in more patients on the early combination plan than the step-up plan (59% versus 43%; P = 0.03), as was ACR Pedi 70 (81% versus 62%; P = 0.008), but generalizability was limited by missing data. PROMIS measures improved in all groups, but without significant differences. Twenty serious adverse events were reported (mostly infections).

Conclusion: Achievement of clinically inactive disease without glucocorticoids did not significantly differ between groups at 12 months. While there was a significantly higher likelihood of early combination therapy achieving inactive disease according to the clinical JADAS-10 and ACR Pedi 70, these results require further exploration.

Trial registration: ClinicalTrials.gov NCT02593006.

© 2021 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

Figures

Figure 1
Figure 1
Disposition of the study patients. A total of 444 participants were screened, and 401 were enrolled. One patient was determined not to have polyarticular juvenile idiopathic arthritis (JIA) and was excluded from the analysis. Of the 400 analyzable participants at baseline, 257 (64%) were started on the step‐up consensus treatment plan (CTP), 100 (25%) on the early combination CTP, and 43 (11%) on the biologic first CTP. Eighteen participants were lost to follow‐up: 2 withdrew consent and 16 moved to a non‐participating clinical site. Of the patients lost to follow‐up, 2 patients were lost to follow‐up after the baseline visit, 2 patients after the 3 month visit, 2 patients after the 6 month visit, and 12 patients after the 9 month visit, leaving 382 participants with at least 12 months of follow‐up data available (250 in the step‐up CTP group, 94 in the early combination CTP group, and 38 in the biologic first CTP group). Of these 382 participants, 44 missed the 12‐month primary end point visit, leaving a total of 338 evaluable CTP participants for the primary end point (222 in the step‐up CTP group, 81 in the early combination CTP group, and 35 in the biologic first CTP group). CID = clinically inactive disease.
Figure 2
Figure 2
Percentage of patients with polyarticular juvenile idiopathic arthritis in the step‐up consensus treatment plan (CTP) group, early combination CTP group, and biologic first CTP group with inactive disease (ID), low disease activity, moderate disease activity, and high disease activity, according to the clinical Juvenile Arthritis Disease Activity Score in 10 joints (JADAS‐10), throughout the study period.
Figure 3
Figure 3
Patient‐Reported Outcomes Measurement Information System pain interference (A) and mobility (B) T scores over time in patients with juvenile idiopathic arthritis in the step‐up consensus treatment plan (CTP) group, early combination CTP group, and biologic first CTP group. Shaded areas indicate the mean and expected SD (50 ± 10) in the healthy population. Higher T scores indicate more pain or improved mobility. For both measures, all groups improved over time. There were no significant differences between the CTP groups.

References

    1. Sacks JJ, Helmick CG, Luo YH, Ilowite NT, Bowyer S. Prevalence of and annual ambulatory health care visits for pediatric arthritis and other rheumatologic conditions in the United States in 2001–2004. Arthritis Rheum 2007;57:1439–45.
    1. Denardo BA, Tucker LB, Miller LC, Szer IS, Schaller JG. Demography of a regional pediatric rheumatology patient population: affiliated children's arthritis centers of New England. J Rheumatol 1994;21:1553–61.
    1. Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 1996;23:1981–7.
    1. Oen KG, Cheang M. Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum 1996;26:575–91.
    1. Krause ML, Crowson CS, Michet CJ, Mason T, Muskardin TW, Matteson EL. Juvenile idiopathic arthritis in Olmsted County, Minnesota, 1960–2013. Arthritis Rheumatol 2016;68:247–54.
    1. Beukelman T, Kimura Y, Ilowite NT, Mieszkalski K, Natter MD, Burrell G, et al. The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. Pediatr Rheumatol Online J 2017;15:30.
    1. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005;52:3554–62.
    1. Ringold S, Seidel KD, Koepsell TD, Wallace CA. Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 2009;48:972–7.
    1. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N, for the Childhood Arthritis and Rheumatology Research Alliance (CARRA), the Pediatric Rheumatology Collaborative Study Group (PRCSG), and the Paediatric Rheumatology International Trials Organisation (PRINTO) . American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011;63:929–36.
    1. Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Schöntube M, et al. Long‐term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2392–401.
    1. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002;29:1989–99.
    1. Packham JC, Hall MA, Pimm TJ. Long‐term follow‐up of 246 adults with juvenile idiopathic arthritis: predictive factors for mood and pain. Rheumatology (Oxford) 2002;41:1444–9.
    1. Zak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long‐term follow‐up study. Rheumatology (Oxford) 2000;39:198–204.
    1. Seid M, Opipari L, Huang B, Brunner HI, Lovell DJ. Disease control and health‐related quality of life in juvenile idiopathic arthritis. Arthritis Rheum 2009;61:393–9.
    1. Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, et al. Long‐term outcomes in juvenile idiopathic arthritis: eighteen years of follow‐up in the population‐based Nordic Juvenile Idiopathic Arthritis cohort. Arthritis Care Res (Hoboken) 2020;72:507–16.
    1. Tynjala P, Vahasalo P, Tarkiainen M, Kröger L, Aalto K, Malin M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE‐JIA): a multicentre randomised open‐label clinical trial. Ann Rheum Dis 2011;70:1605–12.
    1. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:2012–21.
    1. Beukelman T, Guevara JP, Albert DA, Sherry DD, Burnham JM. Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. J Rheumatol 2007;34:1918–24.
    1. Cron RQ, Sharma S, Sherry DD. Current treatment by United States and Canadian pediatric rheumatologists. J Rheumatol 1999;26:2036–8.
    1. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, for the Pediatric Rheumatology Collaborative Study Group . Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763–9.
    1. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810–20.
    1. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio‐Pérez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double‐blind, placebo‐controlled withdrawal trial. Lancet 2008;372:383–91.
    1. Ringold S, Angeles‐Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non‐systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheumatol 2019;71:846–63.
    1. Ringold S, Weiss PF, Colbert RA, DeWitt EM, Lee T, Onel K, et al. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new‐onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2014;66:1063–72.
    1. Consolaro A, Negro G, Gallo MC, Bracciolini G, Ferrari C, Schiappapietra B, et al. Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three‐variable juvenile arthritis disease activity score. Arthritis Care Res (Hoboken) 2014;66:1703–9.
    1. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med 2010;151:203–5.
    1. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni‐Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658–66.
    1. Morgan EM, Mara CA, Huang B, Barnett K, Carle AC, Farrell JE, et al. Establishing clinical meaning and defining important differences for Patient‐Reported Outcomes Measurement Information System (PROMIS) measures in juvenile idiopathic arthritis using standard setting with patients, parents, and providers. Qual Life Res 2017;26:565–86.
    1. Filocamo G, Consolaro A, Schiappapietra B, Dalprà S, Lattanzi B, Magni‐Manzoni S, et al. A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report. J Rheumatol 2011;38:938–53.
    1. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202–9.
    1. McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 2013;32:3388–414.
    1. Ridgeway G, McCaffrey D, Morral A, Griffin BA, Burgette L. twang: Toolkit for Weighting and Analysis of Nonequivalent Groups. July 2021. URL: https://CRAN.R‐.
    1. Van Buuren S, Groothuis‐Oushoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw 2011;45:1–67.
    1. The R project for statistical computing. URL: .
    1. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761–9.
    1. Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva E, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther 2018;20:285.
    1. Shoop‐Worrall SJ, Verstappen SM, McDonagh JE, Baildam E, Chieng A, Davidson J, et al. Long‐term outcomes following achievement of clinically inactive disease in juvenile idiopathic arthritis: the importance of definition. Arthritis Rheumatol 2018;70:1519–29.
    1. Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, et al. Disease‐modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross‐sectional analysis of the CARRA Registry. J Rheumatol 2012;39:1867–74.
    1. Ringold S, Nigrovic PA, Feldman BM, Tomlinson GA, von Scheven E, Wallace CA, et al. The Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans: toward comparative effectiveness in the pediatric rheumatic diseases. Arthritis Rheumatol 2018;70:669–78.
    1. Ong MS, Ringold S, Kimura Y, Schanberg LE, Tomlinson GA, Natter MD, and the CARRA Registry Investigators . Improved disease course associated with early initiation of biologics in polyarticular juvenile idiopathic arthritis: trajectory analysis of a Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans study. Arthritis Rheumatol 2021. doi: 10.1002/art.41892/abstract. E‐pub ahead of print.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir